Metoclopramide S.A.L.F. (Metoclopramide Hydrochloride)

Metoclopramide works by competitively blocking dopamine D2 receptors in the chemoreceptor trigger zone and gastrointestinal tract, which reduces the emetic signal. It also increases acetylcholine activity, promoting coordinated gastric contractions and faster gastric emptying.

The appropriate dose of Metoclopramide S.A.L.F. is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for Metoclopramide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metoclopramide differs from many antiemetics by acting as a dopamine D2 antagonist and a pro‑kinetic agent, whereas drugs like ondansetron target serotonin receptors. This dual action makes Metoclopramide useful for both nausea control and enhancing gastric motility, but it also carries a distinct side‑effect profile.

Metoclopramide S.A.L.F. should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability.

The medication is supplied as an injectable solution and is administered either intramuscularly or intravenously by a qualified healthcare professional. The route and rate of administration depend on the clinical indication and the prescriber’s orders.

Serious risks include extrapyramidal symptoms such as acute dystonia, tardive dyskinesia, and neuroleptic malignant syndrome. These reactions can be life‑threatening and require immediate medical attention. Monitoring for early signs is essential, especially with prolonged use.

Metoclopramide should be avoided in patients with known hypersensitivity to the drug, those with a history of severe extrapyramidal reactions, and individuals taking interacting medications such as antipsychotics or MAO inhibitors without appropriate medical supervision.